https://www.selleckchem.com/products/ro5126766-ch5126766.html Triple-negative breast cancer (TNBC) is characterised by high pathological complete response to neoadjuvant chemotherapy (NAC). However, refractory and poor NAC responders still face very poor outcome, emphasising the urgent need for tools that facilitate identification of these patients, so that surgery or alternatives to NAC are considered early in the treatment protocol. We combined metabolomics, exosome circulating miRNAsand flow cytometry experimental approaches in TNBC patients at diagnosis with immunohistochemistry in needle biopsy tumours to generate NAC-response predictive models. We also co-cultured and studied crosstalk between isolated patient-derived early myeloid-derived suppressor cells (eMDSCs) and TNBC cancer cell lines. Blood-derived liquid biopsy biomarkers display a novel immunosuppressive profile of tryptophan-derived metabolites and eMDSC levels that significantly predict NAC response. Notably, indoleamine 2,3-dioxygenase 1 (IDO1) expression in tumour cells inversely correlated witour cells and eMDSCs that exacerbates immunosuppression. These results provide a potential new tool to identify poor NAC responders for alternative strategies of treatment, including early surgical resection of the tumour, and to explore in them alternative immune therapies. Identifying CT predictors of mortality in nonelderly healthy patients with COVID-19 pneumonia will aid to distinguish the most vulnerable patients in this age group and thus alter the management. We aimed to evaluate the prognostic value of multiple CT features of COVID-19 pneumonia on initial presentation in nonelderly patients without underlying medical conditions. In this retrospective case-control study, thirty laboratory-confirmed COVID-19 patients with no known major underlying disease who underwent a chest CT scan and expired of pneumonia within the following 30 days after admission, were included as case group. Sixty control sub